JP2014516087A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516087A5
JP2014516087A5 JP2014514933A JP2014514933A JP2014516087A5 JP 2014516087 A5 JP2014516087 A5 JP 2014516087A5 JP 2014514933 A JP2014514933 A JP 2014514933A JP 2014514933 A JP2014514933 A JP 2014514933A JP 2014516087 A5 JP2014516087 A5 JP 2014516087A5
Authority
JP
Japan
Prior art keywords
tocopherol
formulation
butanol
pentanol
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514933A
Other languages
English (en)
Japanese (ja)
Other versions
JP6339011B2 (ja
JP2014516087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041950 external-priority patent/WO2013036309A2/en
Publication of JP2014516087A publication Critical patent/JP2014516087A/ja
Publication of JP2014516087A5 publication Critical patent/JP2014516087A5/ja
Application granted granted Critical
Publication of JP6339011B2 publication Critical patent/JP6339011B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514933A 2011-06-10 2012-06-11 眼へのタンパク質の送出のための持続放出性製剤及びその調製方法 Active JP6339011B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
US61/495,672 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (3)

Publication Number Publication Date
JP2014516087A JP2014516087A (ja) 2014-07-07
JP2014516087A5 true JP2014516087A5 (enExample) 2017-07-27
JP6339011B2 JP6339011B2 (ja) 2018-06-06

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514933A Active JP6339011B2 (ja) 2011-06-10 2012-06-11 眼へのタンパク質の送出のための持続放出性製剤及びその調製方法

Country Status (22)

Country Link
US (1) US9814773B2 (enExample)
EP (1) EP2717914B1 (enExample)
JP (1) JP6339011B2 (enExample)
KR (1) KR20140060274A (enExample)
CN (1) CN103945865B (enExample)
AU (1) AU2012304909B2 (enExample)
BR (1) BR112013031685B1 (enExample)
CA (1) CA2838289C (enExample)
CY (1) CY1122771T1 (enExample)
DK (1) DK2717914T3 (enExample)
ES (1) ES2761340T3 (enExample)
HR (1) HRP20192276T1 (enExample)
HU (1) HUE047737T2 (enExample)
IN (1) IN2013MN02384A (enExample)
LT (1) LT2717914T (enExample)
MX (1) MX359119B (enExample)
PL (1) PL2717914T3 (enExample)
PT (1) PT2717914T (enExample)
RS (1) RS60051B1 (enExample)
SI (1) SI2717914T1 (enExample)
SM (1) SMT202000021T1 (enExample)
WO (1) WO2013036309A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913336C (en) * 2013-05-24 2020-12-15 Icon Bioscience, Inc. Use of sustained release dexamethasone in post-cataract surgery inflammation
JP6629840B2 (ja) * 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
HK1246641A1 (zh) * 2015-03-18 2018-09-14 参天制药株式会社 缓释性医药组合物
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
US10786515B2 (en) * 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
EP3749386B1 (en) 2018-02-09 2026-04-15 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
EP4652999A3 (en) 2018-05-01 2026-02-18 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
WO2019213326A1 (en) 2018-05-01 2019-11-07 Idrop, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
EP4153214A4 (en) 2020-05-22 2024-06-26 Trustees of Boston University Methods and compositions for treating a fibrotic disease
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
TWI353854B (en) * 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20050079202A1 (en) * 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
MX2007003968A (es) * 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
ES2672806T3 (es) * 2009-07-03 2018-06-18 Armbruster Biotechnology Gmbh Injerto óseo y material biocompuesto

Similar Documents

Publication Publication Date Title
KR101341359B1 (ko) 편리하게 이식가능한 서방형 약물 조성물
JP6416154B2 (ja) 眼房内ビマトプロスト注入物による眼圧低下
US9011915B2 (en) Conveniently implantable sustained release drug compositions
Heller Ocular delivery using poly (ortho esters)
CN107184544A (zh) 前房内持续释放治疗药植入物
CA2993340C (en) Intravitreal drug delivery systems for the treatment of ocular conditions
JP6339011B2 (ja) 眼へのタンパク質の送出のための持続放出性製剤及びその調製方法
KR20160100992A (ko) 눈의 병태의 치료를 위한 전방내 이식물
CN109602691A (zh) 持续药物递送植入物
WO2015135306A1 (zh) 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物
Einmahl et al. Ocular biocompatibility of a poly (ortho ester) characterized by autocatalyzed degradation
CN114533648A (zh) 一种阿西替尼眼内植入剂
KR102191180B1 (ko) 안질환 치료용 조성물
Chiang et al. Suprachoroidal drug delivery for VEGF suppression in wet AMD and other diseases with choroidal neovascularization
Jelonek et al. Polyesters and polyester carbonates for controlled drug delivery. Part II. Implantable systems
KR102183669B1 (ko) 이중 약물 방출을 위한 약물 전달체
Augustin et al. Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases
CN102406627B (zh) 一种层层组装马赛克结构药物缓释植片
CN105496947A (zh) 一种药物缓释制剂
CN1846700A (zh) 5-氟尿嘧啶玻璃体腔缓释系统
HK1107672B (en) Conveniently implantable sustained release drug compositions